www.fdanews.com/articles/199651-eu-finalizes-deal-with-jj-for-400-million-doses-of-covid-19-vaccine
![johnson.gif](https://www.fdanews.com/ext/resources/test/Device_Images/johnson.gif?t=1586297888&width=430)
EU Finalizes Deal with J&J for 400 Million Doses of COVID-19 Vaccine
October 22, 2020
Johnson & Johnson has finalized a deal with the European Commission for 400 million doses of its COVID-19 vaccine candidate, Ad26.COV2.S.
Ad26.COV2.S is derived from a common cold virus that is modified to carry a gene from the SARS-CoV-2 virus, which causes the immune system to develop resistance to the coronavirus.
Dosing in a phase 3 trial of Ad26.COV2.S was recently suspended following a reported adverse event. The late-stage trial, which began in September, aims to enroll 60,000 participants across three continents to evaluate a single vaccine dose vs. placebo.